Protein and Polycystic Ovary Syndrome (PCOS)
Assessing the Role of Higher Protein Diets in Managing Metabolic Complications of Polycystic Ovary Syndrome (PCOS)
1 other identifier
interventional
60
1 country
2
Brief Summary
Polycystic ovary syndrome (PCOS) is a significant public health problem and is one of the most common hormonal disturbances affecting women of reproductive age. Women with PCOS are often insulin resistant, increasing their risk for cardiometabolic health problems (e.g., type 2 diabetes, heart disease, high blood pressure, sleep apnea, anxiety, depression, and stroke) especially if they are overweight. Lifestyle modifications, including dietary changes and regular physical activity, may alleviate metabolic dysfunction in women with PCOS and are often the first line of management for patients with PCOS. Several studies have identified protein as a key nutrient for regulation of energy balance, maintenance of skeletal muscle mass, and improving cardiometabolic health across the lifespan. However, the effect of increased protein intake (30% of total energy intake) on cardiometabolic health in women with PCOS has not been well-defined and mechanisms for these effects have not been identified. There is an evident need for well-designed, randomized controlled trials evaluating the efficacy of increased protein intake in women with PCOS on markers of cardiometabolic health. Preliminary data from collaborative projects with the investigators on this proposal suggest that increasing protein in the diet has the potential to improve markers of cardiometabolic health, potentially through improvements in body composition and/or changes in cortisol, energy metabolism, inflammation, and neurological regulators
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2025
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2025
CompletedFirst Submitted
Initial submission to the registry
August 19, 2025
CompletedFirst Posted
Study publicly available on registry
September 8, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 3, 2027
September 8, 2025
September 1, 2025
1.9 years
August 19, 2025
September 2, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Lean body mass
Lean body mass will be measured using dual x-ray absorptiometry.
0 and 16 weeks.
Secondary Outcomes (8)
Body fat mass
0 and 16 weeks
Sleep Duration
Sleep will be measured every 8 weeks (0, 8, and 16 weeks)
Mood
Every 4 weeks (0, 4, 8, 12, 16 weeks)
Quality of Life perception
Every 4 weeks (0, 4, 8, 12, and 16 weeks)
Energy expenditure
Every 4 weeks (0, 4, 8, 12 and 16 weeks)
- +3 more secondary outcomes
Study Arms (4)
Calorie restricted control
ACTIVE COMPARATORControl and Protein
ACTIVE COMPARATORCalorie restricted PCOS
ACTIVE COMPARATORPCOS Protein
ACTIVE COMPARATORInterventions
Follow energy-restricted (10% calorie reduction), higher protein dietary pattern (1.6 g protein/kg body weight)
Follow energy-restricted (10% calorie reduction) dietary pattern for 16 weeks. No restrictions on macronutrient content.
Eligibility Criteria
You may qualify if:
- Females ages 18-50 years
- Confirmed diagnosis of PCOS
- Body mass index (BMI) between 18.5 and 35 kg/m2
- Stable body weight for at least 3 months (+ 5 pounds)
- Willingness to consume both plant- and animal-based protein meals
You may not qualify if:
- Smoking or use of nicotine products
- Smoking, vaping, and/or use of marijuana products
- More than 4 alcoholic beverages per week
- Food allergies or dietary restrictions incompatible with test meals
- Diagnosed diabetes (type 1 or 2) or other preexisting chronic disease(s).
- Use of medications that interfere with study outcomes (e.g., metformin, GLP-1 agonists, etc.)
- Consumption of more than 0.8 g/protein/kg body weight
- Underweight
- Taking nutritional supplements
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Center for Human Nutrition
Fayetteville, Arkansas, 72704, United States
Center for Human Nutrition
Fayetteville, Arkansas, 72704, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
August 19, 2025
First Posted
September 8, 2025
Study Start
August 1, 2025
Primary Completion (Estimated)
June 30, 2027
Study Completion (Estimated)
December 3, 2027
Last Updated
September 8, 2025
Record last verified: 2025-09